

**Correction to
Lancet Oncol 2019;
20: 383–93**

de Bono JS, Concin N, Hong DS, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial. *Lancet Oncol* 2019; **20**: 383–93—In table 2 of this Article, data in the “Any adverse event, n (%)” row were corrected for the grade 3 and grade 4 columns. The Results text was updated to reflect this change: “Treatment-emergent adverse events of grade 3 or worse occurred in 82 (56%) of 147 patients.” These corrections have been made to the online version as of Dec 2, 2019.

**Correction to
Lancet Oncol 2019;
20: 1342–44**

Oladeru OT, Perni S, Williams B. Improving care for the overlooked in oncology: incarcerated patients. *Lancet Oncol* 2019; **20**: 1342–44—In this Comment, the formatting in the panel was incorrect. This correction has been made to the online version as of Dec 2, 2019.

**Correction to
Lancet Oncol 2019;
20: 1349–59**

Nichols AC, Theurer J, Prisman E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. *Lancet Oncol* 2019; **20**: 1349–59—In this Article, the fifth sentence of the third paragraph of the Results, should have been “In general, most QOL scores were similar between the two groups, with the exception of inferior scores regarding EORTC QLQ-C30 pain ($p=0.018$) and EORTC QLQ-H&N35 teeth scores ($p=0.014$) in the TORS plus neck dissection group.” This correction has been made to the online version as of Dec 2, 2019.

**Correction to
Lancet Oncol 2019;
20: 1544–55**

Naing A, Wong DJ, Infante JR, et al. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. *Lancet Oncol* 2019; **20**: 1544–55—In the appendix of this Article, supplementary table 2 has been corrected. The appendix has been updated as of Dec 2, 2019.

**Correction to
Lancet Oncol 2019;
20: e645–52**

Oar A, Moraes FY, Romero Y, Ilbawi A, Yap ML. Core elements of national cancer control plans (NCCPs): a tool to support plan development and review. *Lancet Oncol* 2019; **20**: e645–52—In this Policy Review, affiliations for Mei Ling Yap have been added. This correction has been made to the online version as of Dec 2, 2019.